Showing results (21-30 of 84) with videos related to
Sort By:
Pageof 9
Journal of Pharmaceutical Sciences|March 1, 1992
Factors affecting in vitro protein binding of etoposide in humansR A Fleming, W E Evans, S G Arbuck, et al.Cancer Chemotherapy and Pharmacology|January 1, 1997
Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in miceC F Stewart, W C Zamboni, W R Crom, et al.Clinical Pharmacology and Therapeutics|January 1, 1989
Altered protein binding of etoposide in patients with cancerC F Stewart, J A Pieper, S G Arbuck, et al.Cancer|September 15, 1991
Disposition of high-dose methotrexate in an obese cancer patientR A Fleming, R M Eldridge, C E Johnson, et al.Clinical Pharmacology and Therapeutics|October 1, 1991
Relation of systemic exposure to unbound etoposide and hematologic toxicityC F Stewart, S G Arbuck, R A Fleming, et al.Clinical Pharmacology and Therapeutics|April 1, 1990
Coadministration of naproxen and low-dose methotrexate in patients with rheumatoid arthritisC F Stewart, R A Fleming, C R Arkin, et al.Cancer Research|November 1, 1990
Prospective evaluation of a model for predicting etoposide plasma protein binding in cancer patientsC F Stewart, R A Fleming, S G Arbuck, et al.The Journal of Pharmacology and Experimental Therapeutics|October 1, 1987
Influence of concomitant aspirin or prednisone on methotrexate synovial fluid concentrationC F Stewart, M L Christensen, R P Evens, et al.Cancer Chemotherapy and Pharmacology|January 1, 1992
Pharmacodynamics of three daily infusions of etoposide in patients with extensive-stage small-cell lung cancerA A Miller, E A Tolley, H B Niell, et al.Cancer Chemotherapy and Pharmacology|February 28, 2001
Effect of hemodialysis on topotecan disposition in a patient with severe renal dysfunctionJ D Herrington, J A Figueroa, M N Kirstein, et al.Pageof 9